OAP 189

Drug Profile

OAP 189

Alternative Names: OAP189; PF-05212389; PF-5212389; WYE-155189

Latest Information Update: 12 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Obesity therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 09 Aug 2012 Discontinued - Phase-I for Obesity in USA (SC)
  • 09 Aug 2012 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (SC)
  • 11 Aug 2011 Pfizer completes a phase I trial in Type-2 diabetes mellitus in USA (NCT00970593)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top